NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Forecasted to Post Q1 2023 Earnings of ($0.11) Per Share

NeuBase Therapeutics, Inc. (NASDAQ:NBSEGet Rating) – Analysts at Oppenheimer issued their Q1 2023 EPS estimates for NeuBase Therapeutics in a note issued to investors on Tuesday, January 10th. Oppenheimer analyst H. Singh anticipates that the company will post earnings per share of ($0.11) for the quarter. Oppenheimer currently has a “Market Perform” rating on the stock. The consensus estimate for NeuBase Therapeutics’ current full-year earnings is ($0.95) per share. Oppenheimer also issued estimates for NeuBase Therapeutics’ Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.08) EPS, Q4 2023 earnings at ($0.09) EPS, FY2023 earnings at ($0.32) EPS, FY2024 earnings at ($0.33) EPS, FY2025 earnings at ($0.46) EPS and FY2026 earnings at ($0.65) EPS.

Other analysts also recently issued research reports about the stock. Chardan Capital downgraded shares of NeuBase Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, October 17th. Royal Bank of Canada downgraded shares of NeuBase Therapeutics from an “outperform” rating to a “sector perform” rating in a research report on Tuesday, October 18th.

NeuBase Therapeutics Trading Up 2.8 %

NBSE stock opened at $0.23 on Thursday. NeuBase Therapeutics has a twelve month low of $0.17 and a twelve month high of $2.34. The company has a market capitalization of $7.60 million, a P/E ratio of -0.22 and a beta of 0.82. The firm has a 50 day simple moving average of $0.22 and a 200-day simple moving average of $0.53.

Hedge Funds Weigh In On NeuBase Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. First Manhattan Co. acquired a new position in NeuBase Therapeutics in the first quarter worth $26,000. Perkins Capital Management Inc. boosted its holdings in NeuBase Therapeutics by 22.6% in the second quarter. Perkins Capital Management Inc. now owns 81,500 shares of the company’s stock worth $86,000 after purchasing an additional 15,000 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of NeuBase Therapeutics by 20.2% during the third quarter. Renaissance Technologies LLC now owns 287,386 shares of the company’s stock valued at $114,000 after acquiring an additional 48,255 shares during the period. State Street Corp boosted its holdings in shares of NeuBase Therapeutics by 18.4% during the first quarter. State Street Corp now owns 68,687 shares of the company’s stock valued at $129,000 after acquiring an additional 10,674 shares during the period. Finally, CM Management LLC boosted its holdings in shares of NeuBase Therapeutics by 21.6% during the third quarter. CM Management LLC now owns 450,000 shares of the company’s stock valued at $178,000 after acquiring an additional 80,000 shares during the period. Institutional investors and hedge funds own 37.21% of the company’s stock.

NeuBase Therapeutics Company Profile

(Get Rating)

NeuBase Therapeutics, Inc, a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.

See Also

Earnings History and Estimates for NeuBase Therapeutics (NASDAQ:NBSE)

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.